AINMF.US NetraMark Holdings Inc.
- Market cap
- USD 40.9M
- P/E
- -
- P/B
- 19.42x
- ROE
- -221.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is AINMF.US undervalued?
Graham numberThe Graham number of NetraMark Holdings Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NetraMark Holdings Inc. fundamental analysis
No fundamental analysis for NetraMark Holdings Inc. yet.
NetraMark Holdings Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NetraMark Holdings Inc.
NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc…
Full company profileNetraMark Holdings Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NetraMark Holdings Inc. annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 113K | 89.3K | 456K | 432K | 746K |
| Operating Income | - | -237K | -5.05M | -7.93M | -5.86M | -3.33M | -5.22M | -6.60M |
| EBITDA | - | - | - | -7.34M | -5.25M | -3.33M | -5.22M | -6.60M |
| Net Income | - | -292K | -5.08M | -13.4M | -14.2M | -3.33M | -5.22M | -6.60M |
| EPS | - | -0.01 | -0.15 | -0.32 | -0.22 | -0.05 | -0.06 | -0.07 |
| Balance Sheet | ||||||||
| Total Assets | - | 1.97M | 8.40M | 9.20M | 1.91M | 208K | 2.18M | 3.43M |
| Total Liabilities | - | 143K | 459K | 1.09M | 824K | 406K | 342K | 445K |
| Shareholders' Equity | - | 1.83M | 7.94M | 8.11M | 1.09M | -199K | 1.83M | 2.98M |
| Cash & Short-term Investments | - | 1.84M | 6.29M | 10.1K | 1.78M | 59.8K | 1.50M | 3.15M |
| Cash Flow | ||||||||
| Operating Cash Flow | -2.00 | -150K | -2.60M | -4.78M | -2.39M | -2.29M | -3.81M | -4.90M |
| Capital Expenditure | 0.00 | 0.00 | 1.58M | 152K | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | -150K | -4.23M | -4.93M | -2.39M | -2.29M | -3.81M | -4.90M |
| Ratios | ||||||||
| ROE | - | -16.0% | -64.0% | -165.8% | -1,305.3% | - | -284.6% | -221.1% |
| ROA | - | -14.8% | -60.5% | -146.2% | -741.9% | -1,605.1% | -239.9% | -192.4% |
| Net Profit Margin | - | - | - | -11,897.3% | -15,872.7% | -730.5% | -1,207.3% | -884.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NetraMark Holdings Inc. dividends
NetraMark Holdings Inc. has not paid dividends in the last 7 fiscal years.
Who owns NetraMark Holdings Inc.
- Insiders 8.93%
- Institutions 0.00%
- Public & others 91.07%
- Shares outstanding 94.6M
- Free float 80.4M
NetraMark Holdings Inc. company profile
- Company name
- NetraMark Holdings Inc.
- Ticker
- AINMF.US
- ISIN
- CA64119M1059
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Technology
- Fiscal year end
- September
- Address
- 1655 Dupont Street, Toronto, ON, Canada, M6P 3T1
- Phone
- 403 681 2549
- Website
- netramark.com
About NetraMark Holdings Inc.
NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada.
NetraMark Holdings Inc. management
10- Mr. George AchilleosPresident, CEO & Director
- Dr. Joseph Geraci Ph.D.Founder, Chief Scientific & Technical Officer and Director
- Mr. Swapan Kakumanu ACA, ACWA, CGACFO & Corporate Secretary · born 1970
- Mr. Josh SpiegelPresident of NetraMark Corp
- Ms. Jaime HackettVice President of Marketing
- Dr. Luca Pani M.D.Chief Innovation & Regulatory Officer and Chief Medical Advisor
- Dr. Kaveh KavoosiHead of Progressive Medicine
- Dr. Angelico Carta M.D.Chief Strategy Officer
- Dr. Jan Sedway Ph.D.Senior Vice President of Clinical Science
- Dr. Panteli Theocharous M.S., Ph.D.Fractional Chief Medical Officer